Variable | Total (N = 255) | With DVT (N = 30) | Without DVT (N = 225) | P value |
---|---|---|---|---|
Age (years), mean ± SD | 41.3 ± 13.93 | 53.73 ± 11.94 | 39.65 ± 13.34 | < 0.001 |
Sex, n(%) | ||||
Men | 69 | 7(23.33%) | 62(27.56%) | 0.62 |
Women | 186 | 23(76.67%) | 163(72.44%) | |
Inpatient stays (days), mean ± SD | 20.47 ± 9.90 | 31.87 ± 17.68 | 18.95 ± 7.14 | < 0.001 |
Inpatient costs (CNY), mean ± SD | 19,627.22±14,019.56 | 38,178.44 ± 30,309.69 | 17,153.73 ± 7190.18 | < 0.001 |
Comorbidity, n(%) | ||||
Hematological abnormality (anemia, leukopenia) | 13(5.10%) | 1(3.33%) | 12(5.33%) | 0.64 |
Connective tissue diseases | 39(15.29%) | 5(16.67%) | 34(15.11%) | 0.82 |
Thyroid dysfunction | 22(8.63%) | 3(10.00%) | 19(8.44%) | 0.78 |
Diabetes mellitus type 2 | 12(4.71%) | 3(10.00%) | 9(4.00%) | 0.14 |
Hypertension | 27(10.59%) | 5(16.67%) | 22(9.78%) | 0.25 |
Dyslipidemia | 80(31.37%) | 5(16.67%) | 75(33.33%) | 0.06 |
Smoking | 42(16.47%) | 9(30%) | 33(14.67%) | 0.06 |
Etiology, n(%) | ||||
NMOSD | 116(45.49%) | 13(43.33%) | 103(45.78%) | 0.85 |
First attack | 68(26.67%) | 6(20%) | 62(27.56%) | 0.38 |
Relapses | 48(18.82%) | 7(23.33%) | 41(18.22%) | |
Infection | 57(22.35%) | 9(30%) | 48(21.33%) | 0.35 |
CIS | 47(18.43%) | 4(13.33%) | 43(19.11%) | 0.62 |
Vascular myelopathy | 9(3.53%) | 1(3.33%) | 8(3.56%) | 0.71 |
Neoplastic | 5(1.96%) | 1(3.33%) | 4(1.78%) | 0.47 |
Compressive | 3(1.18%) | 0 | 3(1.33%) | 1.00 |
Nutritional | 3(1.18%) | 0 | 3(1.33%) | 1.00 |
Neurosarcoidosis | 2(0.78%) | 0 | 2(0.89%) | 1.00 |
Idiopathic | 13(5.10%) | 2(6.67%) | 11(4.89%) | 0.66 |
Muscle strength of left leg, n (%) | ||||
Grade 0 | 19(7.45%) | 8(26.67%) | 11(4.89%) | < 0.001 |
Grade 1 | 7(2.75%) | 2(6.67%) | 5(2.22%) | |
Grade 2 | 14(5.49%) | 5(16.67%) | 9(4.00%) | |
Grade 3 | 25(9.80%) | 4(13.33%) | 21(9.33%) | |
Grade 4 | 73(28.63%) | 5(16.67%) | 68(30.22%) | |
Grade 5 | 117(45.88%) | 6(20.00%) | 111(49.33%) | |
Muscle strength of right leg, n (%) | ||||
Grade 0 | 19(7.45%) | 8(26.67%) | 11(4.89%) | < 0.001 |
Grade 1 | 10(3.92%) | 4(13.33%) | 6(2.67%) | |
Grade 2 | 11(4.31%) | 4(13.33%) | 7(3.11%) | |
Grade 3 | 21(8.24%) | 4(13.33%) | 17(7.56%) | |
Grade 4 | 68(26.67%) | 8(26.67%) | 60(26.67%) | |
Grade 5 | 126(49.41%) | 2(6.67%) | 124(55.11%) | |
Location of lesions, n (%) | ||||
Cervical | 204(80.00%) | 25(83.33%) | 179(79.56%) | 0.63 |
Thoracic | 133(52.16%) | 17(56.67%) | 116(51.56%) | 0.60 |
Lumbar | 8(3.14%) | 1(3.33%) | 7(3.11%) | 1.00 |
Segments of lesions, mean ± SD | 5.20 ± 3.56 | 6.77 ± 4.98 | 5 ± 3.30 | 0.06 |
Enhancement of lesions, n (%) | ||||
Yes | 115(45.10%) | 13(43.33%) | 102(45.33%) | 0.60 |
No | 108(42.35%) | 11(36.67%) | 97(43.11%) | |
Unknown | 32(12.55%) | 6(20.00%) | 26(11.56%) | |
Internals between LETM symptoms onset and US screening(days), mean ± SD | 18.45 ± 7.40 | 21.40 ± 10.26 | 18.07 ± 6.87 | 0.025 |
Coagulogram abnormal, n (%) | 108(42.35%) | 14(46.67%) | 94(41.78%) | 0.61 |
Baseline D-dimer elevated, n (%) | 24(9.41%) | 17(56.67%) | 7(3.11%) | <0.001 |